ClinicalTrials.gov
ClinicalTrials.gov Menu

Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03614923
Recruitment Status : Not yet recruiting
First Posted : August 3, 2018
Last Update Posted : August 7, 2018
Sponsor:
Information provided by (Responsible Party):
AnaptysBio, Inc.

Brief Summary:
A study to evaluate the safety and efficacy multiple doses of Etokimab in subjects with Chronic Rhinosinusitis with Nasal Polyps.

Condition or disease Intervention/treatment Phase
Chronic Rhinosinusitis Biological: Etokimab Biological: Placebo Phase 2

Detailed Description:
This study is a Phase II, randomized, placebo controlled, double-blind, multi-dose study to evaluate the efficacy and safety of Etokimab in subjects with Chronic Rhinosinusitis with Nasal Polyps.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Double-Blind, Placebo-Controlled Multi-dose Study to Investigate Etokimab (ANB020) Activity in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
Estimated Study Start Date : October 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Arm Intervention/treatment
Active Comparator: Dose 1
SC administration, Q4W
Biological: Etokimab
SC, Q4W
Other Name: ANB020

Active Comparator: Dose 2
SC administration, Q8W
Biological: Etokimab
SC, Q8W
Other Name: ANB020

Placebo Comparator: Placebo
SC administration, Q4W
Biological: Placebo
SC, Placebo Q4W




Primary Outcome Measures :
  1. Change From Baseline in Nasal Polyp Score (NPS) to Week 16 [ Time Frame: Week 16 ]
    Total scoring 0-8, scoring of 0-4 [0 - no polyps, 4 - large polyps causing complete obstruction] bilateral

  2. Change From Baseline in Sino-Nasal Outcome Test -22 (SNOT-22) Score from Week 16 [ Time Frame: Week 16 ]
    Total scoring 0-110, scoring of 0-5 [0 - no problem, 5 - problem as bad as it can be] (22 items)


Secondary Outcome Measures :
  1. Change From Baseline in Smell Test from Week 16 [ Time Frame: Week 16 ]
  2. Change from Baseline in Nasal Peak Inspiratory Flow from Week 16 [ Time Frame: Week 16 ]
  3. Change in sinus opacification as assessed by CT scan using the Lund-Mackay score [ Time Frame: Week 16 ]
    Total Scoring of 0 - 24, ostiomeatal complex 0 or 2 (obstructed) for each sinus group (6), bilateral



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinically confirmed diagnosis of CRSwNP
  • Nasal polyp score ≥ 5 out of a maximum score for both nostrils (with at least a score of 2 for each nostril).
  • SNOT-22 score > 7.
  • Presence of at least two of the following symptoms prior to screening: nasal blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); facial pain/pressure; reduction or loss of smell
  • Body mass index (BMI) of 18 to 38 kg/m2 (inclusive) and total body weight >50 kg (110 lb). BMI=weight (kg)/(height [m2]).

Exclusion Criteria:

  • Use of investigational drugs or prohibited therapy for this study within 2 months before screening or 5 half-lives, whichever is longer.
  • Have experienced severe life threatening anaphylactic reactions.
  • Participation in any interventional study for the treatment of CRSwNP in the 6 months before screening.
  • If female, is pregnant or lactating, or intend to become pregnant during the study period.
  • History (or suspected history) of alcohol or substance abuse.
  • Current smokers or former smokers with a smoking history of ≥15 pack years. If a patient has less than 15 pack years smoking history, he or she should have quit smoking at least 6 months before screening to enroll in the study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03614923


Contacts
Contact: Kham Phenis 858-362-6295 info@anaptysbio.com
Contact: Allison Marquette 858-362-6295 info@anaptysbio.com

Sponsors and Collaborators
AnaptysBio, Inc.
Investigators
Study Director: Marco Londei, MD AnaptysBio, Inc.

Responsible Party: AnaptysBio, Inc.
ClinicalTrials.gov Identifier: NCT03614923     History of Changes
Other Study ID Numbers: ANB020-006
First Posted: August 3, 2018    Key Record Dates
Last Update Posted: August 7, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by AnaptysBio, Inc.:
ANB020
Etikomab
CRSwNP

Additional relevant MeSH terms:
Sinusitis
Nasal Polyps
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Polyps
Pathological Conditions, Anatomical